Teleflex Incorporated (NYSE:TFX) – Investment analysts at Jefferies Group dropped their Q3 2017 earnings estimates for Teleflex in a research note issued to investors on Thursday. Jefferies Group analyst R. Denhoy now expects that the medical technology company will post earnings of $1.99 per share for the quarter, down from their prior forecast of $2.03. Jefferies Group has a “Buy” rating and a $230.00 price objective on the stock. Jefferies Group also issued estimates for Teleflex’s FY2017 earnings at $8.22 EPS, Q1 2018 earnings at $2.12 EPS, Q2 2018 earnings at $2.39 EPS, Q3 2018 earnings at $2.44 EPS, Q4 2018 earnings at $2.70 EPS, FY2019 earnings at $10.98 EPS and FY2020 earnings at $12.39 EPS.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.13. The business had revenue of $528.60 million during the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.89 earnings per share.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/teleflex-incorporated-to-post-q3-2017-earnings-of-1-99-per-share-jefferies-group-forecasts-nysetfx.html.

Several other brokerages have also recently issued reports on TFX. Needham & Company LLC reissued a “buy” rating on shares of Teleflex in a report on Friday. BidaskClub cut Teleflex from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Barclays PLC reissued a “buy” rating on shares of Teleflex in a report on Monday, June 26th. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $228.00 price objective for the company in a report on Friday, June 23rd. Finally, Deutsche Bank AG boosted their price objective on Teleflex from $213.00 to $220.00 and gave the company a “buy” rating in a report on Monday, May 8th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $221.17.

Shares of Teleflex (NYSE TFX) opened at 214.26 on Monday. The firm has a 50-day moving average price of $207.61 and a 200-day moving average price of $195.00. The stock has a market cap of $9.64 billion, a PE ratio of 44.47 and a beta of 1.05. Teleflex has a 12 month low of $136.53 and a 12 month high of $217.97.

Several institutional investors have recently made changes to their positions in TFX. Asset Planning Services Ltd. acquired a new position in shares of Teleflex during the first quarter valued at $116,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Teleflex during the first quarter valued at $155,000. OLD Mutual Customised Solutions Proprietary Ltd. raised its position in shares of Teleflex by 200.0% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after buying an additional 600 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Teleflex during the second quarter valued at $200,000. Finally, Harvey Capital Management Inc. acquired a new position in shares of Teleflex during the second quarter valued at $207,000. Hedge funds and other institutional investors own 92.95% of the company’s stock.

In related news, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $199.93, for a total value of $39,986.00. Following the completion of the transaction, the director now owns 8,080 shares in the company, valued at approximately $1,615,434.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP John Deren sold 2,246 shares of Teleflex stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $194.07, for a total value of $435,881.22. Following the completion of the transaction, the vice president now owns 3,989 shares of the company’s stock, valued at approximately $774,145.23. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,546 shares of company stock valued at $2,079,856. 2.39% of the stock is owned by company insiders.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Tuesday, August 15th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $1.36 annualized dividend and a dividend yield of 0.63%. Teleflex’s dividend payout ratio is presently 26.00%.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.